AstraZeneca Takes a Two-Billion-Dollar Position in Summit

Company AstraZeneca; Summit Therapeutics Event Type Equity Investment and Clinical Collaboration Modality Bispecific Antibody; Antibody-Drug Conjugate Asset Ivonescimab; Sonesitatug Vedotin Target PD-1/VEGF; CLDN18.2 Disease Area Gastrointestinal Cancers Summary AstraZeneca agreed to invest $2.0 billion in newly issued Summit Therapeutics convertible preferred equity and to test…